CSL

Commonwealth Serum Laboratories (CSL) was founded in Australia in 1916 to meet the healthcare needs of a nation impacted by war. Over the years, CSL has played a crucial role in providing Australians with quick access to significant medical innovations from the 20th century, such as insulin, penicillin, and vaccines for diseases like influenza and polio. CSL Limited became a registered company in 1991 and joined the Australian Securities Exchange (ASX) in 1994. Since its incorporation, CSL has expanded by acquiring several companies. Among them are Aventis Behring, now recognized as the global biotechnology leader CSL Behring; Nabi, a U.S. plasma collection firm that contributed to the establishment of CSL Plasma, the leading plasma collection enterprise; the Novartis influenza vaccine division, now part of Seqirus, the second-largest influenza vaccine producer in the world; Calimmune, known for its advancements in gene-modification and cell delivery technologies; and Vitaeris, a biopharmaceutical company dedicated to developing canakinumab for organ transplant patients facing rejection. The rich and diverse history of these acquisitions has solidified CSL's position as an innovative leader on the global stage.

National

English

Online/Digital

Outlet metrics

Domain Authority

Ranking

Global

#383456

United States

#259740

Finance/Finance

#3143

Traffic sources

Monthly visitors

Articles

Beyond Swelling: Living With Hereditary Angioedema (HAE) Means Living With Stress and Uncertainty Between Attacks

May 13, 2024 | csl.com

A rare condition, HAE, causes unpredictable swelling attacks that can be life-threatening. Day-to-day, patients live with the ever-present worry: When will the next attack strike?
A Promising Finding Funded by Uplifting Athletes

Mar 20, 2024 | csl.com | Eric Monticello

Enlarged lymph nodes are a symptom of the rare condition, Castleman disease, but swollen lymph nodes are also a symptom of many other conditions. And that’s one reason it’s difficult to diagnose Castleman disease, said Michael Gonzalez, Ph.D. and Director of Basic and Translational Research at University of Pennsylvania’s Perelman School of Medicine. The condition caused by a hyperactive immune system can damage organs or even be fatal.
Daily Sustainability Practices to Try

Mar 7, 2024 | csl.com | Eric Monticello

Alfredo Álvarez, a project manager with CSL Vifor in Gijón, Spain, is helping create and execute a vision for how Patient Blood Management (PBM) can be implemented in health care. PBM acknowledges the risks of anemia, blood loss and bleeding disorders. As the World Health Organization describes, it’s “a systematic, multidisciplinary, multiprofessional concept to routinely minimize for these risk factors,” which places the patient at the center of care.
FDA Leaders Sound the Alarm About U.S. Vaccination Trends

Feb 21, 2024 | csl.com | Eric Monticello

As vaccination rates fall in the United States, leaders at the U.S. Food and Drug Administration (FDA) are calling upon doctors, pharmacists and others in the clinical and biomedical community to educate the public “in plain language” about the health benefits of vaccines.
Explainer: How Are Medicines Developed?

Feb 14, 2024 | csl.com | Eric Monticello

Patients wait eagerly for new treatments, but it takes years to fully investigate, conceive of and test a new medicine. The National Organization for Rare Disorders (NORD), which advocates for rare disease patients, recently launched a new course that helps explain the process.
Green Collar Jobs of CSL: Kieran Dowling

Feb 1, 2024 | csl.com | Eric Monticello

Kieran Dowling, a Technical Logistics Senior Manager based in the United Kingdom, believes in running a no-fail operation. The cargo he’s responsible for – vaccines – must get from point A to point B. Working with the Global Logistics team, Dowling takes pride in ensuring trade routes are ironclad and having a contingency plan at all times. He’s also a self-starter looking for ways to lessen his department’s impact on the environment.
Tell Your Patient Story

Jan 31, 2024 | csl.com | Eric Monticello

Imagine dying six times, living to tell about it and becoming a therapist in the process. It’s the true story of Dr. Brittany Clayborne, who survived a rare form of peripartum cardiomyopathy, a heart transplant and cancer. The harrowing, psychologically draining experience motivated her to become a mental health advocate for people with critical illness. Now, she’s booked by organizations and universities across the United States to share her story of perseverance.
Cheering On Rare Disease Researchers

Jan 30, 2024 | csl.com | Eric Monticello

Preparations are underway for draft day February 3 at Philadelphia’s Lincoln Financial Field, but these recruits excel in something other than football. Every year, Uplifting Athletes (UA), a nonprofit organization dedicated to rare disease patients, selects 10 promising scientists in its Young Investigator Draft at the Philadelphia Eagles stadium. Each draftee receives a $20,000 grant to pursue game-changing research into rare conditions.
What Doctors Wear Matters to Patients

Jan 25, 2024 | csl.com | Eric Monticello

Watch any movie and you can always pick out the doctor because he or she is in a white coat. It’s a longtime custom, but some are asking if it’s still necessary – especially in light of the working conditions doctors experienced during the COVID-19 pandemic. A recently published journal article looked at two studies – one in 2017 and one in 2022 – and found that patient preference for formal attire, including the doctor’s white coat, dropped following the pandemic.
LEAD Grants for European Patient Groups

Jan 23, 2024 | csl.com | Eric Monticello

When they have the resources they need, patient advocacy groups can accelerate positive change for the rare disease community. CSL Behring’s LEAD Grant Program in Europe, now accepting applications, helps patient organizations fund key projects. LEAD stands for Local Empowerment for Advocacy Development and the program offers up to €10,000 for each selected European advocacy organization.